Skip to main content
SpringerLink
Log in

Prostate Cancer

  • Chapter
Stereotactic Body Radiation Therapy

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

  • 2204 Accesses

Abstract

Stereotactic body radiation therapy (SBRT) is a promising treatment option for prostate cancer. Hypofractionation regimens such as SBRT may be more advantageous compared to conventional regimens because low α/β ratio of prostate cancer has high sensitivity to dose per fraction. In addition, the estimated higher α/β ratio of rectum and a smaller and tighter margin with SBRT is expected to provide acceptable toxicity despite higher dose per fraction. The successful implementation of SBRT for prostate cancer requires accurate target and normal tissues delineation, patient/tumor immobilization, image guidance or tumor tracking, advanced treatment planning and delivery. Here we describe the rationale and effectiveness of SBRT in the management of prostate cancer, its technical aspects, clinical applications, and treatment toxicities. Clinical case examples will be included with clinical settings, treatment plans, and outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Akimoto T, Muramatsu H, Takahashi M, Saito J, Kitamoto Y, Harashima K, Miyazawa Y, Yamada M, Ito K, Kurokawa K, Yamanaka H, Nakano T, Mitsuhashi N, Niibe H (2004) Rectal bleeding after hypofractionated radiotherapy for prostate cancer: correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding. Int J Radiat Oncol Biol Phys 60(4):1033–1039. doi:10.1016/j.ijrobp.2004.07.695, S0360-3016(04)02091-7 [pii]

    Article  PubMed  Google Scholar 

  • Asano Y, Inoue Y, Ikeda Y, Kikuchi K, Hara T, Taguchi C, Tokushige T, Maruo H, Takeda T, Nakamura T, Fujita T, Kumagai Y, Hayakawa K (2011) Phase I clinical study of NMK36: a new PET tracer with the synthetic amino acid analogue anti-[18F]FACBC. Ann Nucl Med 25(6):414–418. doi:10.1007/s12149-011-0477-z

    Article  PubMed  CAS  Google Scholar 

  • Boike TP, Lotan Y, Cho LC, Brindle J, Derose P, Xie XJ, Yan J, Foster R, Pistenmaa D, Perkins A, Cooley S,Timmerman R (2011) Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol. doi:10.1200/JCO.2010.31.4377, JCO.2010.31.4377 [pii]

  • Bolzicco G, Favretto MS, Scremin E, Tambone C, Tasca A (2010) Guglielmi R Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results. Technol Cancer Res Treat 9(5): 473–477

    Google Scholar 

  • Brenner DJ (2004) Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys 60(4):1013–1015. doi:10.1016/j.ijrobp.2004.04.014, S0360301604006480 [pii]

    Article  PubMed  Google Scholar 

  • Brenner DJ, Hall EJ (1999) Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43(5):1095–1101. S0360-3016(98)00438-6 [pii]

    Article  PubMed  CAS  Google Scholar 

  • Brenner D, Armour E, Corry P, Hall E (1998) Sublethal damage repair times for a late-responding tissue relevant to brachytherapy (and external-beam radiotherapy): implications for new brachytherapy protocols. Int J Radiat Oncol Biol Phys 41(1):135–138. S0360-3016(98)00029-7[pii]

    Article  PubMed  CAS  Google Scholar 

  • Dasu A (2007) Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol (R Coll Radiol) 19(5):289–301. doi:10.1016/j.clon.2007.02.007, S0936-6555(07)00518-3 [pii]

    Article  CAS  Google Scholar 

  • Dewit L, Oussoren Y, Bartelink H, Thames HD (1989) The effect of cis-diamminedichloroplatinum(II) on radiation damage in mouse rectum after fractionated irradiation. Radiother Oncol 16(2):121–128. 0167-8140(89)90029-7 [pii]

    Article  PubMed  CAS  Google Scholar 

  • Dubray BM, Thames HD (1994) Chronic radiation damage in the rat rectum: an analysis of the influences of fractionation, time and volume. Radiother Oncol 33(1):41–47. 0167-8140(94)90084-1 [pii]

    Article  PubMed  CAS  Google Scholar 

  • Fowler JF, Ritter MA, Chappell RJ, Brenner DJ (2003) What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 56(4):1093–1104. S0360301603001329 [pii]

    Article  PubMed  Google Scholar 

  • Freeman DE,King CR (2011) Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol 6(1):3. doi:10.1186/1748-717X-6-3, 1748-717X-6-3 [pii]

    Google Scholar 

  • Friedland JL, Freeman DE, Masterson-McGary ME, Spellberg DM (2009) Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat 8(5):387–392

    PubMed  CAS  Google Scholar 

  • Gasinska A, Dubray B, Hill SA, Denekamp J, Thames HD, Fowler JF (1993) Early and late injuries in mouse rectum after fractionated X-ray and neutron irradiation. Radiother Oncol 26(3):244–253. http://qa.accuray.com/Clinical-Development/Clinical-Studies.aspx

    Article  PubMed  CAS  Google Scholar 

  • Jabbari S, Weinberg VK, Kaprealian T, Hsu IC, Ma L, Chuang C, Descovich M, Shiao S, Shinohara K, Roach M, 3rd, Gottschalk AR (2012) Stereotactic body radiotherapy as monotherapy or post-external beam Radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys. doi:10.1016/j.ijrobp.2010.10.026, S0360-3016(10)03447-4 [pii]

  • Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M (2010) Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 10:1. doi:10.1186/1471-2490-10-1, 1471-2490-10-1 [pii]

  • Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M (2011) Stereotactic body radiotherapy as boost for organ-confined prostate cancer. Technol Cancer Res Treat 9(6): 575–582. doi:c4310/Stereotactic-Body-Radiotherapy-as-Boost-for-Organ-confined-Prostate-Cancer-575-582-p17824.html [pii]

    Google Scholar 

  • King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC Jr (2009) Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 73(4):1043–1048. doi:10.1016/j.ijrobp.2008.05.059, S0360-3016(08)02459-0 [pii]

    Article  PubMed  Google Scholar 

  • King CR, Brooks JD, Gill H, Presti JC Jr (2011) Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. doi:10.1016/j.ijrobp.2010.11.054, S0360-3016(10)03677-1 [pii]

    Google Scholar 

  • Kupelian PA, Willoughby TR, Reddy CA, Klein EA,Mahadevan A (2007) Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland clinic experience. Int J Radiat Oncol Biol Phys 68(5): 1424–1430. doi:10.1016/j.ijrobp.2007.01.067, S0360-3016(07)00535-4 [pii]

    Google Scholar 

  • Lindner U, Lawrentschuk N, Trachtenberg J (2010) Image guidance for focal therapy of prostate cancer. World J Urol 28(6):727–734. doi:10.1007/s00345-010-0604-9

    Article  PubMed  CAS  Google Scholar 

  • Livsey JE, Cowan RA, Wylie JP, Swindell R, Read G, Khoo VS, Logue JP (2003) Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. Int J Radiat Oncol Biol Phys 57(5):1254–1259. S0360301603007521 [pii]

    Article  PubMed  Google Scholar 

  • Lloyd-Davies RW, Collins CD, Swan AV (1990) Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years’ experience (1962–1984). Urology 36(2):107–111. doi:10.1016/0090-4295(90)80207-4, 0090-4295(90)80207-4 [pii]

  • Lotan Y, Stanfield J, Cho LC, Sherwood JB, Abdel-Aziz KF, Chang CH, Forster K, Kabbani W, Hsieh JT, Choy H, Timmerman R (2006) Efficacy of high dose per fraction radiation for implanted human prostate cancer in a nude mouse model. J Urol 175(5):1932–1936. doi:10.1016/S0022-5347(05)00893-1, S0022-5347(05)00893-1 [pii]

    Article  PubMed  Google Scholar 

  • Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, Levine M, Sathya J, Choo R, Prichard H, Brundage M, Kwan W (2005) Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23(25):6132–6138. doi:10.1200/JCO.2005.06.153, 23/25/6132 [pii]

    Article  PubMed  Google Scholar 

  • Maciejewski B (2009) Boost in radiotherapy: external beam sunset, brachytherapy sunrise. J Contemp Brachyther 1(1):5–10

    Google Scholar 

  • Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L,Corman J (2007) Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 67(4):1099–1105. doi:10.1016/j.ijrobp.2006.10.050, S0360-3016(06)03369-4 [pii]

    Google Scholar 

  • Martinez AA, Gonzalez J, Ye H, Ghilezan M, Shetty S, Kernen K, Gustafson G, Krauss D, Vicini F, Kestin L (2011) Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys 79(2):363–370. doi:10.1016/j.ijrobp.2009.10.035, S0360-3016(09)03428-2 [pii]

    Article  PubMed  Google Scholar 

  • McNeal JE, Redwine EA, Freiha FS, Stamey TA (1988) Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 12(12):897–906

    Article  PubMed  CAS  Google Scholar 

  • Oermann EK, Suy S, Hanscom HN, Kim JS, Lei S, Yu X, Zhang G, Ennis B, Rohan JP, Piel N, Sherer BA, Borum D, Chen VJ, Batipps GP, Constantinople NL, Dejter SW, Bandi G, Pahira J, McGeagh KG, Adams-Campbell L, Jha R, Dawson NA, Collins BT, Dritschilo A, Lynch JH, Collins SP (2011) Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer. J Hematol Oncol 4:12. doi:10.1186/1756-8722-4-12, 1756-8722-4-12 [pii]

    Article  PubMed  CAS  Google Scholar 

  • Park C, Papiez L, Zhang S, Story M, Timmerman RD (2008) Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 70(3):847–852. doi:10.1016/j.ijrobp.2007.10.059, S0360-3016(07)04460-4 [pii]

    Article  PubMed  Google Scholar 

  • Pawlicki T, Cotrutz C, King C (2007) Prostate cancer therapy with stereotactic body radiation therapy. Front Radiat Ther Oncol 40:395–406. doi:10.1159/0000106049, 10.1159/0000106049 [pii]

    Article  PubMed  Google Scholar 

  • Perez CA (2004) Principles and practice of radiation oncology. Philadelphia, Lippincott Williams & Wilkins

    Google Scholar 

  • Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Konski AA, Movsas B, Greenberg RE, Uzzo RG, Ma CM, McNeeley SW, Buyyounouski MK, Price RA Jr (2006) Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 64(2):518–526. doi:10.1016/j.ijrobp.2005.07.970, S0360-3016(05)02228-5 [pii]

    Article  PubMed  Google Scholar 

  • Pollack A, Buyyounouski M, Horwitz E, Price S, Feigenberg S, Konski A, Greenberg R, Uzzo R, Ma C (2009) Hypofractionation for Prostate cancer: interim results of a randomized trial. Int J Radiat Oncol Biol Phys 75(3):S81–82

    Article  Google Scholar 

  • Rene N, Faria S, Cury F, David M, Duclos M, Shenouda G, Souhami L (2010) Hypofractionated radiotherapy for favorable risk prostate cancer. Int J Radiat Oncol Biol Phys 77(3):805–810. doi:10.1016/j.ijrobp.2009.05.047, S0360-3016(09)00829-3 [pii]

    Article  PubMed  Google Scholar 

  • Ritter M (2008) Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer. Semin Radiat Oncol 18(4):249–256. doi:10.1016/j.semradonc.2008.04.007, S1053-4296(08)00036-2 [pii]

    Article  PubMed  Google Scholar 

  • Schuster DM, Votaw JR, Nieh PT, Yu W, Nye JA, Master V, Bowman FD, Issa MM, Goodman MM (2007) Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 48(1):56–63. 48/1/56 [pii]

    PubMed  CAS  Google Scholar 

  • Siegel R, Naishadham MA, Jemal A (2012) Cancer Statistics. J Clin 62:10–29

    Google Scholar 

  • Soete G, Arcangeli S, De Meerleer G, Landoni V, Fonteyne V, Arcangeli G, De Neve W, Storme G (2006) Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity. Radiother Oncol 80(1):78–81. doi:10.1016/j.radonc.2006.06.005, S0167-8140(06)00247-7 [pii]

    Article  PubMed  Google Scholar 

  • Takashima R, Egawa S, Kuwao S, Baba S (2002) Anterior distribution of Stage T1c nonpalpable tumors in radical prostatectomy specimens. Urology 59(5):692–697. S009042950201525X [pii]

    Article  PubMed  Google Scholar 

  • Tang CI, Loblaw DA, Cheung P, Holden L, Morton G, Basran PS, Tirona R, Cardoso M, Pang G, Gardner S, Cesta A (2008) Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3. Clin Oncol (R Coll Radiol) 20(10):729–737. doi:10.1016/j.clon.2008.08.006, S0936-6555(08)00357-9 [pii]

    Article  CAS  Google Scholar 

  • Tanyi JA, He T, Summers PA, Mburu RG, Kato CM, Rhodes SM, Hung AY, Fuss M (2010) Assessment of planning target volume margins for intensity-modulated radiotherapy of the prostate gland: role of daily inter- and intra-fraction motion. Int J Radiat Oncol Biol Phys 78(5):1579–1585. doi:10.1016/j.ijrobp.2010.02.001, S0360-3016(10)00223-3 [pii]

    Article  PubMed  Google Scholar 

  • Teh BSGY, Wang X, Zhu J, Mai W, Huang Y, Paulino AC, Ittmann MBE (2008) In vitro and in vivo efficacy of ablative hypfractionation radiation/stereotactic body radiation therapy (SBRT) for human prostate cancer. Proceedings Radiological Society of North America Annual Meeting abstr # SSA22-01

    Google Scholar 

  • Terry NH, Denekamp J (1984) RBE values and repair characteristics for colo-rectal injury after caesium 137 gamma-ray and neutron irradiation. II. Fractionation up to ten doses. Br J Radiol 57(679):617–629

    Article  PubMed  CAS  Google Scholar 

  • van der Kogel AJ, Jarrett KA, Paciotti MA, Raju MR (1988) Radiation tolerance of the rat rectum to fractionated X-rays and pi-mesons. Radiother Oncol 12(3):225–232. doi:10.1016/0167-8140(88)90265-4, 0167-8140(88)90265-4 [pii]

    Article  PubMed  Google Scholar 

  • Verma S, Rajesh A (2011) A clinically relevant approach to imaging prostate cancer: review. Am J Roentgenol 196(3 Suppl): S1-10 Quiz S11-14. doi:10.2214/AJR.09.7196, 196/3_Supplement/S1 [pii]

  • Wang JZ, Huang Z, Lo SS, Yuh WT, Mayr NA (2010) A generalized linear-quadratic model for radiosurgery, stereotactic body radiation therapy, and high-dose rate brachytherapy. Sci Transl Med 2(39): 39ra48. doi:10.1126/scitranslmed.3000864, 2/39/39ra48 [pii]

  • Wiegner EA, King CR (2010) Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial. Int J Radiat Oncol Biol Phys 78(2): 442–448. doi:10.1016/j.ijrobp.2009.07.1748, S0360-3016(09)02950-2 [pii]

    Google Scholar 

  • Yeoh EE, Botten RJ, Butters J, Di Matteo AC, Holloway RH, Fowler J (2010) Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys. doi:10.1016/j.ijrobp.2010.07.1984, S0360-3016(10)03031-2 [pii]

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, The Methodist Hospital, Cancer Center and Research Institute, 6565 Fannin, DB1-077, Houston, TX, 77030, USA

    Hiromichi Ishiyama, Angel I. Blanco, Bo Xu, E. Brian Butler & Bin S. Teh

  2. Department of Radiology and Radiation Oncology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan

    Hiromichi Ishiyama

  3. Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA

    Simon S. Lo & Rodney J. Ellis

  4. Department of Internal Medicine, Division of Oncology, University of Texas Health Sciences Center, Houston, TX, USA

    Robert J. Amato

  5. Flushing Radiation Oncology, Flushing, NY, USA

    Alan Katz

  6. ABC Cancer Center, Mexico City, Mexico

    Jose Hinojosa

Authors
  1. Hiromichi Ishiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan Katz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Angel I. Blanco
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jose Hinojosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Simon S. Lo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rodney J. Ellis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bo Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Robert J. Amato
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E. Brian Butler
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Bin S. Teh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bin S. Teh .

Editor information

Editors and Affiliations

  1. , Department of Radiation Oncology, Case Western Reserve University, Euclid Avenue 11100, Cleveland, 44106, Ohio, USA

    Simon S. Lo

  2. , Department of Radiation Oncology, Weil Cornell Medical College, Fannin, Ste#DB1-077 6565, Houston, 77030, Texas, USA

    Bin S. Teh

  3. Cancer Institute, Department of Radiation Oncology, National University Hospital, Lower Kent Ridge Road 5, Singapore, 119074, Singapore

    Jiade J. Lu

  4. , Department of Radiation Oncology, University of Colorado, Aurora, 80045, Colorado, USA

    Tracey E. Schefter

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Ishiyama, H. et al. (2012). Prostate Cancer. In: Lo, S., Teh, B., Lu, J., Schefter, T. (eds) Stereotactic Body Radiation Therapy. Medical Radiology(). Springer, Berlin, Heidelberg. https://doi.org/10.1007/174_2012_649

Download citation

  • DOI: https://doi.org/10.1007/174_2012_649

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-25604-2

  • Online ISBN: 978-3-642-25605-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation